ALHC

Analyst Note: Alignment Healthcare, Inc. (ALHC)

Date: 2026-06-13 Ticker: ALHC

1. Structural Readiness

• Conservative Entry: $21.30
• Current Price: $21.86
• Extension: +2.6% above conservative entry.
• Volatility Context:
• *ATR at Breakout:* 3.5% (Productive). This indicates the structural quality at the time of the breakout was within the historical "productive" range, suggesting a healthy move rather than a chaotic spike.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led As of 2026-06-13, there is no named secular thesis attached to this specific setup. The conviction for this trade is derived entirely from the structural quality of the Coil setup and the immediate business fundamentals disclosed in the most recent earnings cycle. We are not trading a macro narrative (e.g., "Medicare Advantage is the future") as a primary driver here; rather, we are trading the alignment of a high-quality business execution with a confirmed technical breakout. The setup quality and the strength of the Q1/Q2 2026 guidance form the sole basis for the conviction stack.

3. Business Fundamentals

Company Overview: Alignment Healthcare, Inc. operates as a technology-driven Medicare Advantage provider. The company focuses on a consumer-centric model, delivering personalized medical services primarily to elderly individuals and those requiring specific support. Unlike traditional insurers that merely underwrite risk, Alignment directly owns and operates Medicare Advantage programs in specific high-density markets while also orchestrating care services for beneficiaries of unrelated plans.

Business Model & Operations:

• Model: The company generates revenue through earned premiums from Health Maintenance Organization (HMO) and Preferred Provider Organization (PPO) contracts. It leverages a proprietary clinical model to manage high-acuity populations.
• Geographic Footprint: As of the 2026 plan year, the company offers plans in 45 markets across California (22 markets), North Carolina (16 markets), Nevada (2 markets), Arizona (3 markets), and Texas (2 markets).
• Market Position: The company has grown from approximately 13,000 members at inception to 284,800 members as of March 31, 2026. This represents a 30% compound annual growth rate. Despite this growth, the company holds only 6% market share of Medicare Advantage enrollees in its current markets, where approximately 8.4 million seniors are eligible.
• Quality Metrics: 100% of health plan members are enrolled in plans rated 4 stars and above by CMS, indicating a high-quality care experience.

Financial Performance (Source: Earnings Transcript 2026-04-30):

• Q1 2026 Performance: Health plan membership reached 284,800, up 31% year-over-year. Total revenue was $1.2 billion, up 33% year-over-year. Earned premium revenues for the three months ended March 31, 2026, were $1,226.6 million, compared to $918.0 million in the prior year period.
• Q2 2026 Guidance (Management Expectations):
• Membership: 288,000 – 290,000.
• Revenue: $1.30 billion – $1.32 billion.
• Adjusted Gross Profit: $167 million – $177 million.
• Adjusted EBITDA: $50 million – $60 million.
• Full Year 2026 Guidance (Management Expectations):
• Membership: 294,000 – 299,000.
• Revenue: $5.16 billion – $5.21 billion.
• Adjusted EBITDA: $138 million – $163 million.

Operational Efficiency: Management reported that the year-to-date auto-adjudication rate is over 60%, with expectations to drive claims automation even higher throughout 2026. This operational leverage supports the margin expansion implied in the EBITDA guidance.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector ALHC fits the Growth Leader archetype, transitioning into a Margin Inflector as automation scales.

• Growth: The 31% YoY membership growth and 33% revenue growth in Q1 2026 demonstrate top-line acceleration. The guidance for 2026 suggests continued expansion, with membership expected to nearly double from the 2025 baseline (implied by the 30% CAGR from inception).
• Margin Inflector: The focus on high-acuity populations and the push for >60% auto-adjudication are structural levers designed to improve operating leverage. The guidance for Adjusted EBITDA ($138M–$163M for the full year) implies a significant improvement in profitability relative to the revenue base, suggesting the business is moving past the pure investment phase into a scalable profit engine.

Valuation & Conviction Stack:

• Financial Spine: Forward consensus EPS for FY1 is $0.18423 and FY2 is $0.4242. This indicates the market expects a transition to profitability within the next two fiscal years.
• Conviction Drivers:
• Structural Quality: The ATR at breakout (3.5%) was "productive," and the current ATR (5.3%) is in the "high" sweet spot, indicating strong momentum without extreme volatility risk.
• Fundamental Momentum: The 31% membership growth and 33% revenue growth are robust, outpacing typical industry averages for established players.
• Market Opportunity: With only 6% market share in its 45 markets, the company has significant runway for organic growth before hitting saturation.

Rating: The setup is actionable. The combination of a confirmed breakout, strong fundamental growth, and a clear path to profitability (FY2 EPS > $0.40) creates a high-conviction tactical setup.

5. Invalidations, Strengtheners, and Gaps

Invalidation Criteria:

• Fundamental: A significant miss on the Q2 2026 guidance (e.g., membership growth slowing to <10% or EBITDA guidance cut by >20%) would undermine the "Growth Leader" archetype.

Strengtheners:

• Technical: A sustained move higher with ATR remaining in the 4–6% "high" range, confirming the trend is not a one-day spike.
• Fundamental: Confirmation that the auto-adjudication rate exceeds 65% in Q2, further validating the margin inflection thesis.
• Expansion: Announcement of entry into new markets beyond the current 45 markets, leveraging the 8.4 million eligible seniors in the region.

Evidence Gaps:

• Long-term Unit Economics: While EBITDA guidance is provided, specific data on Cost Per Member (CPM) trends over the last 12 months is not explicitly detailed in the provided evidence, though implied by the gross profit guidance.
• Competitive Landscape: There is no specific data on competitor pricing or market share shifts in the provided evidence, only the company's own share (6%).
• Regulatory Environment: No specific mention of upcoming CMS rate changes or regulatory headwinds in the 2026 guidance, though the "durable program" comment suggests management sees stability.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key risks: 1) Technical invalidation via a close below $16.86. 2) Slower than expected adoption of auto-adjudication tools impacting margin expansion. 3) Regulatory changes in Medicare Advantage reimbursement rates not yet priced into guidance. Sizing hint: Position size should account for the 5.3% current ATR; standard sizing applies given the confirmed breakout and high conviction in the growth narrative. Expected path: Management expects membership to reach 288k-290k in Q2 and 294k-299k for the full year, with revenue growing to $5.16B-$5.21B and EBITDA expanding to $138M-$163M as automation drives efficiency. Expected horizon: 6 to 12 months for the full-year guidance to play out and for the stock to re-rate on confirmed profitability. Failure mode to watch: A daily close below $16.86, which would signal a breakdown of the structural support and invalidate the setup.